Pembroke TPI, John G, Puyk B, Howkins K, Clarke R, Yousuf F, Czajkowski M, Godkin A, Salmon J, Yeoman A. Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. World J Hepatol 2023; 15(1): 89-106 [PMID: PMC9896508 DOI: 10.4254/wjh.v15.i1.89]
Corresponding Author of This Article
Thomas Peter Ignatius Pembroke, FRCP, MBBS, PhD, Doctor, Senior Lecturer, Department of Gastroenterology and Hepatology, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom. thomas.pembroke@wales.nhs.uk
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jan 27, 2023; 15(1): 89-106 Published online Jan 27, 2023. doi: 10.4254/wjh.v15.i1.89
Table 1 International Classification of Diseases-10 code case definition for liver disease aetiology, stratified into hierarchical tiers based of clinical importance
Tier 1
Tier 2
Tier 3
Descriptor
ICD-10 code
Descriptor
ICD-10 code
Descriptor
ICD-10 code
Autoimmune liver disease
Autoimmune hepatitis
K75.4
Hepatitis not specified
Inflammatory liver disease unspecified
K76.9
Miscellaneous
Peliosis hepatis
K76.4
Primary biliary cholangitis
K74.3
Other specified inflammatory liver disease
K75.8
Other specified diseases of the liver
K76.8
Granulomatous hepatitis not elsewhere specified
K75.3
Chronic hepatitis not elsewhere classified
K73.0-K73.9
Liver disorders in diseases classified elsewhere
K77
Metabolic liver disease
Haemochromatosis
E83.11
Congestive hepatopathy
Chronic passive congestion of the liver
K76.1
Alpha 1 anti-trypsin deficiency
E88.01
Central haemorrhagic necrosis of the liver
K76.2
Wilson’s disease
E83.01
Hepatic veno-occlusive disease
K76.5
HBV
Hepatitis B without D
B18.1
Toxic liver disease
Toxic liver disease
K71
Hepatitis B with D
B18.0
HCV
Hepatitis C
B18.2
Alcohol-related liver disease
Alcoholic liver disease
K70-K70.9
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease
K76.0
Table 2 International Classification of Diseases-10 codes to define the advanced stages of liver disease
Oesophageal varices without bleeding in diseases specified elsewhere, I98.2
Hepatic failure unspecified K72
Cirrhosis, other, K74.6
Table 3 The number, age and sex of individuals with aetiological liver disease diagnoses in Wales 1999-2019 following application of aetiology hierarchy
Aetiology
n
% of total cohort
Mean/median age (yr)
% male
Tier 1
ArLD
16143
26.1%
54.9/55
67.8%
NAFLD
13390
21.6%
57/58
47%
Metabolic
7131
11.5%
63/67
52.5%
HCV
2889
4.7%
43/41
66.8%
ArLD overlap
2979
4.8%
51.2/51
65.3%
Autoimmune liver diseases
2312
3.7%
61.8/64
20.5%
HBV
904
1.5%
43.5/39
53.3%
Non ArLD overlap
955
1.5%
51.2/51
55.8%
Tier 2
Hepatitis not specified
6069
9.8%
63/66
50.9%
Congestive hepatopathy
894
1.4%
64.7/70
49.6%
Toxic liver disease
820
1.3%
46.3/44
38.4%
Tier 3
Miscellaneous
7430
12%
66.7/70
42%
Table 4 Progression of liver disease over 10 years by aetiology
0
6 mo
1 yr
2 yr
3 yr
5 yr
10 yr
ArLD
Stage 1
48.75
40.27
36.14
31.54
28.36
24.21
19.18
Stage 2
16.52
14.12
12.93
11.75
10.82
9.65
7.87
Stage 3
13.47
13.93
13.92
12.8
11.86
10.18
8.1
Stage 4
4.49
4.8
5.09
5.3
5.33
4.97
4.25
Stage 5
0.63
0.5
0.49
0.44
0.38
0.34
0.34
Stage 6
16.14
26.38
31.43
38.17
43.25
50.64
60.25
NAFLD
Stage 1
86.3
82.52
80.42
77.98
76.25
73.93
70.7
Stage 2
2.54
2.28
2.31
2.21
2.22
2.18
1.98
Stage 3
2.87
2.99
2.87
2.7
2.52
2.29
2.07
Stage 4
0.82
0.93
0.98
1.01
1.01
0.95
0.91
Stage 5
0.4
0.38
0.36
0.28
0.3
0.22
0.24
Stage 6
7.07
10.89
13.07
15.82
17.71
20.43
24.1
Autoimmune liver disease
Stage 1
72.94
66.33
63.31
59.57
56.44
51.89
44.83
Stage 2
10.79
10.53
10.12
9.67
9.07
8.51
7.73
Stage 3
8.7
9.29
9.41
9.07
8.77
7.69
6.83
Stage 4
2.43
2.8
2.84
2.95
3.02
3.21
2.99
Stage 5
0.86
0.9
0.82
0.67
0.63
0.56
0.6
Stage 6
4.29
10.15
13.51
18.07
22.06
28.14
37.03
HBV
Stage 1
88.96
86.25
84.58
82.6
81.46
79.69
78.02
Stage 2
2.5
1.77
1.98
1.98
1.88
1.88
1.88
Stage 3
2.71
2.71
2.5
2.5
2.4
1.98
2.08
Stage 4
0.94
1.04
1.04
0.94
0.94
1.04
1.25
Stage 5
2.19
1.46
1.25
1.25
1.25
0.94
0.83
Stage 6
2.71
6.77
8.65
10.73
12.08
14.48
15.94
HCV
Stage 1
88.02
85.5
83.54
80.68
78.51
75.38
71.59
Stage 2
4.15
3.88
3.94
4.06
4.12
4.06
3.61
Stage 3
2.8
2.59
2.53
2.53
2.59
2.35
2.29
Stage 4
0.87
1.05
1.14
1.17
1.2
1.17
1.2
Stage 5
1.38
1.2
1.17
1.11
1.08
1.17
1.17
Stage 6
2.77
5.78
7.67
10.44
12.49
15.86
20.13
Metabolic
Stage 1
82.03
67.35
63.3
59.25
56.3
52.51
47.7
Stage 2
1.73
1.37
1.29
1.21
1.16
1.11
1.05
Stage 3
1.36
1.24
1.16
1.2
1.07
0.99
0.96
Stage 4
0.63
0.52
0.53
0.57
0.56
0.56
0.49
Stage 5
0.56
0.4
0.24
0.23
0.23
0.28
0.23
Stage 6
13.69
29.12
33.48
37.54
40.69
44.55
49.57
Congestive hepatopathy
Stage 1
70.36
55.3
50.05
43.44
38.58
34.79
31.1
Stage 2
2.24
1.65
1.65
1.07
0.78
0.58
0.58
Stage 3
3.21
3.01
2.62
2.33
2.04
1.94
1.46
Stage 4
2.04
1.75
1.75
1.75
1.94
1.85
2.04
Stage 5
0.68
0.29
0.29
0.29
0.29
0.19
0.19
Stage 6
21.48
38
43.63
51.12
56.37
60.64
64.63
Toxic
Stage 1
80.87
76.09
73.96
71.31
69.48
67.45
62.87
Stage 2
1.22
0.92
1.02
0.81
0.71
0.61
0.61
Stage 3
1.63
1.93
1.73
1.42
1.73
1.53
1.42
Stage 4
3.46
3.15
3.36
3.26
3.36
3.15
2.95
Stage 5
0.31
0.2
0.2
0.2
0.2
0.2
0.1
Stage 6
12.51
17.7
19.74
22.99
24.52
27.06
32.04
Miscellaneous
Stage 1
91.24
80.46
75.76
70.45
67.05
63.04
57.4
Stage 2
0.62
0.57
0.49
0.42
0.35
0.31
0.29
Stage 3
0.94
0.97
0.99
0.94
0.94
0.9
0.75
Stage 4
0.37
0.34
0.37
0.39
0.39
0.35
0.37
Stage 5
0.62
0.64
0.57
0.45
0.38
0.35
0.28
Stage 6
6.21
17.02
21.82
27.35
30.89
35.04
40.91
Citation: Pembroke TPI, John G, Puyk B, Howkins K, Clarke R, Yousuf F, Czajkowski M, Godkin A, Salmon J, Yeoman A. Rising incidence, progression and changing patterns of liver disease in Wales 1999-2019. World J Hepatol 2023; 15(1): 89-106